Small cell lung cancer (SCLC) often responds well to initial treatment before later relapsing. Researchers are continuing to investigate new treatments, such as targeted therapy and immunotherapy ...

Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical ...

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common complication of small cell lung cancer (SCLC). It can cause many symptoms related to low sodium or other electrolyte ...

The Food and Drug Administration (FDA) has granted traditional approval to Imdelltra ® (tarlatamab-dlle) for the treatment of adults with extensive stage small cell lung cancer (ES-SCLC) with disease ...

New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small cell lung cancer, with a disabled quality control cell cycle checkpoint ...

The FDA has approved Imfinzi for some adults with limited-stage small cell lung cancer. The Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for adults with limited-stage small ...

Novel therapies targeting molecular pathways, including DLL3 and PARP inhibitors, show promise in improving SCLC survival outcomes. Tarlatamab, a DLL3-targeting bispecific T-cell engager, achieved a ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GSK’227, now known as risvutatug rezetecan, for the treatment of small-cell lung cancer (SCLC), according to a news ...

Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...

“Lung cancer, though common and serious, still has many misconceptions,” says Ian Bostock, MD, a thoracic surgeon at Miami Cancer Institute in Florida. “Clearing these myths helps patients and ...